Table 3: Prevalence of comorbidities at the time of initiation of the hemodialysis therapy and the monthly per capita income.

Signs and Symptoms < US$300.00 (%)
(n=89)
≥ US$300.00 and
< US$450.00 (%)
(n=84)
≥ US$450.00 (%)
(n=41)
Total (%)
(n=214)
p&
Hypertension 75 (84.27) 76 (90.48) 38 (92.68) 189 (88.32) 0.29
Diabetes Mellitus 42 (47.19) 29 (34.52) 16 (39.02) 87 (40.65) 0.23
Diabetic neuropathy 29 (32.58) 20 (23.81) 9 (21.95) 58 (27.10) 0.31
Chronic Kidney Disease -Mineral and Bone Disorder 20 (22.47) 19 (22.62) 9 (21.95) 48 (22.43) 1.00
Diabetic retinopathy 24 (26.97) 9 (10.71) 10 (24.39) 43 (20.09) 0.02
Dyslipidemia 16 (17.98) 15 (17.86) 6 (14.63) 37 (17.29) 0.92
Peripheral arterial disease 15 (16.85) 15 (17.86) 6 (14.63) 36 (16.82) 0.92
Stroke 11 (12.36) 10 (11.90) 8 (19.51) 29 (13.55) 0.49
Osteoporosis 10 (11.24) 10 (11.90) 6 (14.63) 26 (12.15) 0.86
Myocardial infarction 7 (7.87) 10 (11.90) 6 (14.63) 23 (10.75) 0.48
Heart failure 7 (7.87) 11 (13.10) 5 (12.20) 23 (10.75) 0.50
Diabetic feet 12 (13.48) 6 (7.14) 4 (9.76) 22 (10.28) 0.39
Angina pectoris 10 (11.24) 6 (7.14) 2 (4.88) 18 (8.41) 0.43
Amputation 7 (7.87) 5 (5.95) 4 (9.76) 16 (7.48) 0.75
Epigastric pain 6 (6.74) 3 (3.57) 1 (2.44) 10 (4.67) 0.53
Hepatitis B virus infection 3 (3.37) 2 (2.38) 1 (2.44) 6 (2.80) 1.00
Hepatitis C virus infection 2 (2.25) 3 (3.57) 0 (0.00) 5 (2.34) 0.53
HIV infection 1 (1.12) 1 (1.19) 0 (0.00) 2 (0.93) 1.00

& The Chi-square test was used to compare the frequencies of each event. The level of significance was set at p < 0.05.